Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Delcath Wins Third Orphan Drug Designation
Delcath is enrolling patients in a phase II clinical trial testing its proprietary drug delivery system, known as the Delcath Percutaneous Hepatic Perfusion (PHP) System, with ultra high
Delcath is enrolling patients in a phase II clinical trial testing its proprietary drug delivery system, known as the Delcath Percutaneous Hepatic Perfusion (PHP) System, with ultra high
Medivation has declared the new clinical results from a phase 1-2 trial evaluating MDV3100, a next-generation androgen receptor antagonist, in castration-resistant prostate cancer (CRPC) patients. The new findings,
syngo Suite, Siemens web-enabled radiology information system (RIS) and picture archiving and communications system (PACS) with post-processing applications, computer-aided detection (CAD) applications, and embedded speech recognition, consists of
The company estimates that Diclofenac Sodium eye drops will generate revenues of $0.5 million during the first year of sales. Diclofenac Sodium eye drops are meant for the
The Chinese market is growing rapidly, and demand for Luminex’s multiplexing technologies among scientists in China is strong, said Patrick J. Balthrop, president and chief executive officer of
This guidance sets out the MHRA’s views on the interpretation of the medical devices regulations. It should not be considered to be an authoritative statement of the law
Advanced Life Sciences has announced that the FDA’s Anti Infective Drugs Advisory Committee voted in majority that Restanza (cethromycin) demonstrated safety for the outpatient treatment of adults with
Nanogen on May 14, 2009, has filed a voluntary petition under chapter 11 bankruptcy protection and had inked the agreement to sell substantially all of its assets to
The agreement ensures that the hospital is equipped with solutions that put clinicians’ and patients’ needs at the centre of care. Medical equipment will be replaced in line
Stiefel has declared the completion and analysis of phase III clinical trial for Hyphanox (itraconazole) tablets, for the treatment of onychomycosis. The study compared once daily oral dosing